Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 6/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.39 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 2/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.39 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | F12 | P00748 | 2/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964957 | 0.82 | MAPK1 (0.42) | ACVR1TGFBR1FYNALKHRH3 | |
| SCHEMBL29964557 | 0.80 | MAPKAPK2 (0.41) | ACVR1TGFBR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL29964634 | 0.80 | MAPK1 (0.41) | ACVR1TGFBR1FYNALKHRH3 | |
| SCHEMBL29965169 | 0.80 | FYN (0.38) | ACVR1TGFBR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL31079351 | 0.79 | TDP2 (0.43) | ACVR1TGFBR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL31079426 | 0.78 | FYN (0.37) | ACVR1TGFBR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL29964516 | 0.77 | OGA (0.40) | ACVR1TGFBR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL29964007 | 0.77 | FYN (0.41) | ACVR1TGFBR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL29965037 | 0.77 | ACVR1 (0.41) | ACVR1TGFBR1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL29965014 | 0.76 | TGFBR1 (0.52) | ACVR1TGFBR1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | ACVR1 3323/4885TGFBR1 4134/4885BMPR1B 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.